Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer immunotherapy

Phagocytic cooperativity by tumour macrophages

Nature Biomedical Engineering volume 7, pages 1057–1059 (2023)Cite this article

Subjects

Disrupting the CD47–SIRPα checkpoint in tumour macrophages and delivering a tumour-opsonizing monoclonal antibody maximizes the macrophages’ cooperative phagocytic potency.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Combining CD47 blockade with tumour-opsonizing antibodies leads to macrophage activation and to the disruption of spatial organization in the tumour.

References

  1. Cassetta, L. & Pollard, J. W. Nat. Rev. Drug Discov. 17, 887–904 (2018).

    Article  CAS  PubMed  Google Scholar 

  2. Kloosterman, D. J. & Akkari, L. Cell 186, 1627–1651 (2023).

    Article  CAS  PubMed  Google Scholar 

  3. Willingham, S. B. et al. Proc. Natl Acad. Sci. USA 109, 6662–6667 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Weiskopf, K. et al. Science 341, 88–91 (2013).

    Article  CAS  PubMed  Google Scholar 

  5. Weiskopf, K. Eur. J. Cancer 76, 100–109 (2017).

    Article  CAS  PubMed  Google Scholar 

  6. Bouwstra, R., van Meerten, T. & Bremer, E. Clin. Transl Med. 12, e943 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Dooling, L. J. et al. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-023-01031-3 (2023).

    Article  PubMed  Google Scholar 

  8. Zhao, X. W. et al. Proc. Natl. Acad. Sci. USA 108, 18342–18347 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Roberts, A. W. et al. eLife 8, e45957 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Klichinsky, M. et al. Nat. Biotechnol. 38, 947–953 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Cham, L. B. et al. Cell Rep. 31, 107494 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Sockolosky, J. T. et al. Proc. Natl Acad. Sci. USA 113, E2646–2654 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Bian, Z. et al. Nat. Commun. 12, 3229 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Srivastava, R. M. et al. Clin. Cancer Res. 19, 1858–1872 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Advani, R. et al. N. Engl. J. Med. 379, 1711–1721 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Ingram, J. R. et al. Proc. Natl Acad. Sci. USA 114, 10184–10189 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Whitehead Institute for Biomedical Research, Cambridge, MA, USA

    Asaf Maoz & Kipp Weiskopf

  2. Dana-Farber Cancer Institute, Boston, MA, USA

    Asaf Maoz & Kipp Weiskopf

Authors
  1. Asaf Maoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kipp Weiskopf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kipp Weiskopf.

Ethics declarations

Competing interests

A.M. and K.W. have filed US patent applications related to macrophage-based cancer therapies via the Whitehead Institute. K.W. holds relevant patents and royalties (via Stanford University, the Whitehead Institute and Gilead Sciences), is a co-founder, scientific advisory board member and equity holder of ALX Oncology, DEM Biopharma and Solu Therapeutics, has been a scientific advisor of Carisma Therapeutics and owns stock of Ginkgo Bioworks.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maoz, A., Weiskopf, K. Phagocytic cooperativity by tumour macrophages. Nat. Biomed. Eng 7, 1057–1059 (2023). https://doi.org/10.1038/s41551-023-01088-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41551-023-01088-0

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer